Literature DB >> 24690066

Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report.

Gabrielle Crépeau-Gendron1, Sophie L'Heureux.   

Abstract

AIM: Our case report addresses the use of clozapine in patients who have a history of quetiapine XR-induced neutropenia. There are no current guidelines for this situation.
METHODS: We present the case of a young woman treated with clozapine at a first-episode psychosis clinic after a moderate quetiapine XR-induced neutropenia (0,5-1,0 × 10(9)  L(-1) ).
RESULTS: The patient was successfully treated with clozapine and lithium, with less psychotic symptoms and a better level of functioning. The neutrophil count remained normal during the treatment period, which has been longer than a year.
CONCLUSION: The outcome of this case supports the notion that clinicians could consider introducing clozapine in treatment-refractory patients who have a history of quetiapine XR-induced neutropenia, with close blood monitoring. Lithium co-administration may play a role in maintaining a normal neutrophil count.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  agranulocytosis; antipsychotic agent; clozapine; neutropenia; quetiapine

Mesh:

Substances:

Year:  2014        PMID: 24690066     DOI: 10.1111/eip.12134

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  2 in total

1.  Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis.

Authors:  John Mark Franco; Saraschandra Vallabhajosyula; Timothy John Griffin
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 2.  Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.

Authors:  Samantha Alvarez-Herrera; Raúl Escamilla; Oscar Medina-Contreras; Ricardo Saracco; Yvonne Flores; Gabriela Hurtado-Alvarado; José Luis Maldonado-García; Enrique Becerril-Villanueva; Gilberto Pérez-Sánchez; Lenin Pavón
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.